Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Pathol Res Pract. 2024 Oct;262:155556. doi: 10.1016/j.prp.2024.155556. Epub 2024 Aug 23.
To investigate the correlation between programmed death ligand-1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) and evaluate the prognostic value of PD-L1 and TILs in Chinese triple-negative breast cancer (TNBC) patients with different molecular subtype METHODS: This retrospective study was conducted at 2020. Specifically, the pre-chemotherapy clinical data and non-stained tissue blocks of 465 TNBC patients visited the Fudan University Shanghai Cancer Center (FUSCC) between 2008 and 2014 were collected, with their blocks sliced and stained using PD-L1(SP142), and the outcome of subsequent chemotherapy obtained in 2020. The relapse-free survival (RFS) of the study population was calculated. The baseline PD-L1 expression status correlations with TILs and molecular subtypes were assessed using Spearman's rank correlation analysis and the Kruskal-Wallis test. Kaplan-Meier survival analyses were undertaken to evaluate the prognosis value of TILs and PD-L1 expression.
PD-L1 expression status on IC was moderately and positively correlated with stromal tumor-infiltrating lymphocytes (sTILs) (r = 0.502, P <0.001) and iTILs (r = 0.410, P < 0.001), respectively. PD-L1 expression status and TILs showed significant differences among molecular subtypes (P < 0.001), with the highest proportion of PD-L1+ and high TILs patients observed in the immunomodulatory (IM) subtype. TILs were significantly associated with RFS. Moreover, sTILs could act as an independent predictor of RFS (RR 0.953, 95 % CI 0.920 ∼ 0.987, P = 0.007), while PD-L1 expression status did not show the same prognostic significance.
The incorporation of pre-treatment TILs and PD-L1 expression status as valuable tools for optimizing patient selection for immunotherapy and managing the risks associated with chemotherapy in Chinese TNBC patients.
The data sets generated and analyzed during the current study are available from the corresponding author.
研究程序性死亡配体-1（PD-L1）表达与肿瘤浸润淋巴细胞（TILs）的相关性，并评估 PD-L1 和 TILs 在不同分子亚型的中国三阴性乳腺癌（TNBC）患者中的预后价值。
本回顾性研究于 2020 年进行。具体来说，收集了 2008 年至 2014 年期间在复旦大学附属肿瘤医院（FUSCC）就诊的 465 例 TNBC 患者的化疗前临床数据和未经染色的组织块，并用 PD-L1（SP142）对其进行染色，并在 2020 年获得随后化疗的结果。计算研究人群的无复发生存期（RFS）。使用 Spearman 秩相关分析和 Kruskal-Wallis 检验评估基线 PD-L1 表达状态与 TILs 和分子亚型的相关性。采用 Kaplan-Meier 生存分析评估 TILs 和 PD-L1 表达的预后价值。
IC 上的 PD-L1 表达状态与间质肿瘤浸润淋巴细胞（sTILs）（r = 0.502，P <0.001）和 iTILs（r = 0.410，P <0.001）呈中度正相关。PD-L1 表达状态和 TILs 在分子亚型之间存在显著差异（P <0.001），免疫调节（IM）亚型中 PD-L1+和高 TILs 患者的比例最高。TILs 与 RFS 显著相关。此外，sTILs 可作为 RFS 的独立预测因子（RR 0.953，95%CI 0.920~0.987，P = 0.007），而 PD-L1 表达状态则没有显示出相同的预后意义。
在接受化疗的中国 TNBC 患者中，将治疗前 TILs 和 PD-L1 表达状态作为优化免疫治疗患者选择和管理化疗相关风险的有价值工具。
本研究生成和分析的数据集中的数据集可从相应作者处获得。
